Product Description

Formula & Concentration

VIMPAT (lacosamide)* Tablet, Film Coated for Oral use

VIMPAT (lacosamide)* Injection for Intravenous use

Manufacturer

UCB

Indications

Vimpat®  (lacosamide) CV is indicated 1) for the treatment of partial-onset seizures in patients 1 month of age and older 2) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older

Product Options

Package Size

NDC #

Presentation

Injection for intravenous use, CV 200 mg/20 mL

00131-1810-67

10 vials

Tablets, CV 50 mg

00131-2477-35

60 tablets

Tablets, CV 100 mg

00131-2478-35

60 tablets

Tablets, CV 150 mg

00131-2479-35

60 tablets

Tablets, CV 200 mg

00131-2480-35

60 tablets

Oral solution, CV 10 mg/200 mL

00131-5410-72

oral solution (200 mL glass bottle)

Tablets, CV 50 mg

00131-2477-60

60 unit dose tablets

Tablets, CV 100 mg

00131-2478-60

60 unit dose tablets

Tablets, CV 150 mg

00131-2479-60

60 unit dose tablets

Tablets, CV 200 mg

00131-2480-60

60 unit dose tablets

Shelf Life and Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]

*VIMPAT is a Schedule V controlled substance.